US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Therapeutics

26.34

+0.47001.82%

Post-market: 26.340.00000.00%16:20 EDT

Volume:226.52K

Turnover:5.88M

Market Cap:741.37M

PE:-11.26

High:26.44

Open:26.34

Low:24.86

Close:25.87

Loading ...

Overview Company News Filings

Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics

Press Release: Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

Press Release: Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF

Altamira Therapeutics Earnings Call: Growth Amid Challenges

Optimistic Buy Rating for Larimar Therapeutics Amid Promising Phase II Study and Regulatory Progress

LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025

Quince Therapeutics to Present at Citizens Life Sciences Conference

Analysts Conflicted on These Healthcare Names: QuidelOrtho (QDEL) and Enliven Therapeutics (ELVN)

Atossa Therapeutics Gets US Patent Covering (Z)-endoxifen Breast Cancer Treatment

MT Newswires Live

Rakovina Therapeutics Reports 2024 Financial Results and Strategic Advances in AI-Driven Cancer Therapies

SpringWorks Therapeutics Cut to Neutral From Buy by HC Wainwright & Co.

Evercore ISI Initiates Coverage on OnKure Therapeutics With Outperform Rating

MT Newswires Live

Guggenheim Starts Edgewise Therapeutics With Buy Rating, $41 Price Target

MT Newswires Live

Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025

Astria Therapeutics to Present at Upcoming Citizens Life Sciences Conference

Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders

CytoMed Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

Context Therapeutics presents preclinical data on CT-95

HC Wainwright Downgrades Springworks Therapeutics to Neutral From Buy, Adjusts Price Target to $47 From $74

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/LENZ/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LENZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":26.34,"timestamp":1746820800000,"preClose":25.87,"halted":0,"volume":226520,"hourTrading":{"tag":"盘后","latestPrice":26.34,"preClose":26.34,"latestTime":"16:20 EDT","volume":400,"amount":10536,"timestamp":1746822000343},"delay":0,"floatShares":11456571,"shares":28146154,"eps":-2.338654,"marketStatus":"Closed","change":0.47,"latestTime":"05-09 16:00:00 EDT","open":26.34,"high":26.44,"low":24.86,"amount":5880456.606978,"amplitude":0.061075,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.338654,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1747036800000},"marketStatusCode":5,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":25.87,"preHourTrading":{"tag":"盘前","latestPrice":26.3,"preClose":25.87,"latestTime":"09:29 EDT","volume":321,"amount":8435.569914,"timestamp":1746797398443},"postHourTrading":{"tag":"盘后","latestPrice":26.34,"preClose":26.34,"latestTime":"16:20 EDT","volume":400,"amount":10536,"timestamp":1746822000343},"volumeRatio":0.867442,"impliedVol":0.6531,"impliedVolPercentile":0.8182},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","floatShares":11456571,"roa":"-25.64%","roe":"-38.94%","lyrEps":-2.338654,"volumeRatio":0.867442,"shares":28146154,"dividePrice":0,"high":26.44,"amplitude":0.061075,"preClose":25.87,"low":24.86,"week52Low":14.42,"pbRate":"3.63","week52High":38.93,"institutionHeld":0,"latestPrice":26.34,"eps":-2.338654,"divideRate":0,"volume":226520,"delay":0,"ttmEps":-2.338654,"open":26.34,"prevYearClose":28.87,"prevWeekClose":29.52,"prevMonthClose":28.515,"prevQuarterClose":25.71,"fiveDayClose":29.52,"twentyDayClose":18.54,"sixtyDayClose":24.84},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LENZ\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532708910","title":"Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2532708910","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532708910?lang=en_us&edition=fundamental","pubTime":"2025-05-01 19:00","pubTimestamp":1746097200,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass. & MONTREAL, May 01, 2025----Repare Therapeutics Inc.  , a leading clinical-stage precision oncology company, today announced that it has out-licensed its discovery platforms, including certain platform and program intellectual property, to DCx Biotherapeutics Corporation , a newly-launched Canadian biotechnology company developing next generation precision drug conjugates and supported by Amplitude Ventures. Additionally, DCx will retain certain preclinical research personnel, acquire lease rights to certain laboratory facilities in Montreal and acquire certain laboratory equipment.Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Repare has utilized its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Repare’s clini","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/repare-therapeutics-announces-licensing-discovery-110000323.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","LENZ","BK4139","RPTX"],"gpt_icon":0},{"id":"2532168078","title":"Press Release: Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2532168078","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532168078?lang=en_us&edition=fundamental","pubTime":"2025-05-01 19:00","pubTimestamp":1746097200,"startTime":"0","endTime":"0","summary":"BOSTON, May 01, 2025  -- Tango Therapeutics, Inc. , today announced that it will report first quarter 2025 financial results on May 12, 2025, before the open of the U.S. financial markets. The company does not intend to hold a conference call.Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","TNGX","BK4007","BK4139"],"gpt_icon":0},{"id":"2532078248","title":"Press Release: Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2532078248","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532078248?lang=en_us&edition=fundamental","pubTime":"2025-05-01 19:00","pubTimestamp":1746097200,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., May 01, 2025  -- Foghorn Therapeutics Inc. , a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the election of Neil Gallagher, M.D., Ph.D., and Stuart Duty, to its Board of Directors.\"Neil and Stuart are experienced leaders with decades of deep and multifaceted understanding of the biotechnology industry,\" said Adrian Gottschalk, President and Chief Executive Officer of Foghorn. \"We are pleased to welcome them to our Board of Directors and will leverage their strategic insights as we further advance our pipeline.\". Stuart Duty brings over 30 years of experience in finance and investment banking in biotechnology and specialty pharmaceuticals. Most recently, he served as a Senior Managing Director at Guggenheim Securities, LLC where he advised senior executives and boards on a range of financing activities and strategic transactions. Previously, he held senior ro","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK4022","BK4139","LENZ","BK4232","BK4007","FHTX"],"gpt_icon":0},{"id":"2532075868","title":"Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF","url":"https://stock-news.laohu8.com/highlight/detail?id=2532075868","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532075868?lang=en_us&edition=fundamental","pubTime":"2025-05-01 19:00","pubTimestamp":1746097200,"startTime":"0","endTime":"0","summary":"AUSTIN, Texas, May 1, 2025 /PRNewswire/ -- Rein Therapeutics  , a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, and Qureight Ltd, a Core Imaging Laboratory developing deep-learning image analytics, today announced a collaboration for the integration of Qureight's deep-learning platform into Rein's planned Phase 2 trial of its lead asset LTI-03, a novel, multi-pathway, Caveolin-1-related peptide, for the treatment of idiopathic pulmonary fibrosis .Dr. Muhunthan Thillai, Chief Executive Officer of Qureight, said, \"We're delighted that our core platform and AI technology will be supporting Rein Therapeutics in advancing its treatment, LTI-03, for patients with IPF. Our AI tools will provide precise, quantitative insights into","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/rein-therapeutics-qureight-ltd-announce-110000614.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rein-therapeutics-qureight-ltd-announce-110000614.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4139","BK4007","CSD","RNTX"],"gpt_icon":0},{"id":"2532883019","title":"Altamira Therapeutics Earnings Call: Growth Amid Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2532883019","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532883019?lang=en_us&edition=fundamental","pubTime":"2025-05-01 08:01","pubTimestamp":1746057675,"startTime":"0","endTime":"0","summary":"Altamira Therapeutics Ltd. (($CYTOF)) has held its Q4 earnings call. Read on for the main highlights of the call. Altamira Therapeutics Ltd. recent...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/altamira-therapeutics-earnings-call-growth-amid-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/altamira-therapeutics-earnings-call-growth-amid-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"gpt_icon":0},{"id":"2532092630","title":"Optimistic Buy Rating for Larimar Therapeutics Amid Promising Phase II Study and Regulatory Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2532092630","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532092630?lang=en_us&edition=fundamental","pubTime":"2025-05-01 05:35","pubTimestamp":1746048936,"startTime":"0","endTime":"0","summary":"William Blair analyst Myles Minter has reiterated their bullish stance on LRMR stock, giving a Buy rating today. Myles Minter has given his Buy rat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-larimar-therapeutics-amid-promising-phase-ii-study-and-regulatory-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-larimar-therapeutics-amid-promising-phase-ii-study-and-regulatory-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","PRGS"],"gpt_icon":0},{"id":"2532232096","title":"LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2532232096","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532232096?lang=en_us&edition=fundamental","pubTime":"2025-05-01 04:30","pubTimestamp":1746045000,"startTime":"0","endTime":"0","summary":"SAN DIEGO, April 30, 2025  -- LENZ Therapeutics, Inc. , a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, May 7th, 2025, at 4:30 p.m. EDT to report its first quarter 2025 financial results and recent corporate highlights.To participate in the conference call via telephone, dial  715-9871  or  307-1963  and enter code 8251197. The live webcast can be accessedhereand on the LENZ Therapeutics website atwww.LENZ-tx.comin the Investors & Media section. A replay of the webcast will be available on the Company’s website for 30 days following the event.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lenz-therapeutics-report-first-quarter-203000233.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LENZ","BK4007"],"gpt_icon":0},{"id":"2532090858","title":"Quince Therapeutics to Present at Citizens Life Sciences Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2532090858","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532090858?lang=en_us&edition=fundamental","pubTime":"2025-05-01 04:05","pubTimestamp":1746043500,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., April 30, 2025----Quince Therapeutics, Inc. , a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, will present at the Citizens Life Sciences Conference taking place in New York City on Wednesday, May 7, 2025 beginning at 3:30 p.m. Eastern Time.A live webcast of the presentation will be accessible on the Events page under the News & Events heading of Quince’s Investor Relations website at ir.quincetx.com. An archive of the webcast will be available shortly following the end of the live event.Quince Therapeutics, Inc.  is a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases. For more information on the company and its latest news, visit www.quincetx.com and follow Quince on social media platforms LinkedIn, Fac","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/quince-therapeutics-present-citizens-life-200500002.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","QNCX","BK4007","LENZ"],"gpt_icon":0},{"id":"2532670590","title":"Analysts Conflicted on These Healthcare Names: QuidelOrtho (QDEL) and Enliven Therapeutics (ELVN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2532670590","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532670590?lang=en_us&edition=fundamental","pubTime":"2025-05-01 02:50","pubTimestamp":1746039046,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on QuidelOrtho (QDEL – Research Report) and Enliven Therapeutics (EL...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-quidelortho-qdel-and-enliven-therapeutics-elvn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-quidelortho-qdel-and-enliven-therapeutics-elvn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ELVN","BK4137","BK4198","BK4139","BK4082","HCSG","LENZ","BK4007","QDEL"],"gpt_icon":0},{"id":"2532068430","title":"Atossa Therapeutics Gets US Patent Covering (Z)-endoxifen Breast Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2532068430","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532068430?lang=en_us&edition=fundamental","pubTime":"2025-04-30 23:41","pubTimestamp":1746027717,"startTime":"0","endTime":"0","summary":"Atossa Therapeutics  said Wednesday that the US Patent and Trademark Office granted a new patent covering highly pure and stable enteric oral formulations of -endoxifen, a breast cancer treatmentThe patent includes 58 claims, encompassing various formulations and therapeutic methods for hormone-dependent breast and reproductive tract disorders, the company said.Atossa shares rose 1.9% in recent Wednesday trading.Price: 0.81, Change: +0.02, Percent Change: +1.89","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","Z","BK4079","BK4551","BK4588","BK4007","BK4548","LENZ","ATOS","BK4585"],"gpt_icon":0},{"id":"2531736030","title":"Rakovina Therapeutics Reports 2024 Financial Results and Strategic Advances in AI-Driven Cancer Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2531736030","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531736030?lang=en_us&edition=fundamental","pubTime":"2025-04-30 21:18","pubTimestamp":1746019086,"startTime":"0","endTime":"0","summary":"An announcement from Rakovina Therapeutics Inc ( ($TSE:RKV) ) is now available. Rakovina Therapeutics Inc. announced its 2024 financial results and...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/rakovina-therapeutics-reports-2024-financial-results-and-strategic-advances-in-ai-driven-cancer-therapies?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/rakovina-therapeutics-reports-2024-financial-results-and-strategic-advances-in-ai-driven-cancer-therapies?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","BK4007"],"gpt_icon":0},{"id":"2531603213","title":"SpringWorks Therapeutics Cut to Neutral From Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2531603213","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531603213?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:48","pubTimestamp":1746017280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SWTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 30, 2025 08:48 ET (12:48 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","SWTX"],"gpt_icon":0},{"id":"2531031031","title":"Evercore ISI Initiates Coverage on OnKure Therapeutics With Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2531031031","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531031031?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:11","pubTimestamp":1746015089,"startTime":"0","endTime":"0","summary":"Evercore ISI Initiates Coverage on OnKure Therapeutics With Outperform Rating","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OKUR","LENZ"],"gpt_icon":0},{"id":"2531031030","title":"Guggenheim Starts Edgewise Therapeutics With Buy Rating, $41 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2531031030","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531031030?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:09","pubTimestamp":1746014966,"startTime":"0","endTime":"0","summary":"Edgewise Therapeutics (EWTX) has an average rating of buy and mean price target of $42.78, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","EWTX"],"gpt_icon":0},{"id":"2531031444","title":"Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531031444","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531031444?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:00","pubTimestamp":1746014400,"startTime":"0","endTime":"0","summary":"CHICAGO and FORT WORTH, Texas, April 30, 2025  -- Actuate Therapeutics, Inc.  , a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta , today announced that Daniel Schmitt, President & Chief Executive Officer of Actuate will present at the Citizens Life Sciences Conference 2025 taking place May 7-8 in New York, NY.The webcast of the presentation will be accessible in the Investor section of the Actuate website.The Actuate management team will participate in one-on-one investor meetings during this event. Investors interested in meeting with management should contact their Citizens JMP representative.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/actuate-therapeutics-participate-citizens-life-120000302.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4007","BK4139","ACTU"],"gpt_icon":0},{"id":"2531031408","title":"Astria Therapeutics to Present at Upcoming Citizens Life Sciences Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2531031408","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531031408?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:00","pubTimestamp":1746014400,"startTime":"0","endTime":"0","summary":"BOSTON, April 30, 2025----Astria Therapeutics, Inc. , a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Citizens Life Sciences Conference on Wednesday, May 7th at 10:30am ET.Astria Contact: Investor Relations and Media: Elizabeth Higginsinvestors@astriatx.com","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astria-therapeutics-present-upcoming-citizens-120000514.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ATXS","BK4139","LENZ","BK4007"],"gpt_icon":0},{"id":"2531039959","title":"Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2531039959","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531039959?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:45","pubTimestamp":1746013500,"startTime":"0","endTime":"0","summary":"BETHESDA, Md., April 30, 2025  -- Gain Therapeutics, Inc.  , a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced an oral poster presentation at the International Association of Parkinsonism and Related Disorders  30th World Congress on Parkinson's Disease and Related Disorders, being held May 7th-10th in New York City, NY.Details of the oral and poster presentation are as follows:. Presentation Title: GT-02287, A Clinical-stage Allosteric GCase Modulator For The Treatment Of Parkinson’s Disease, Protects Dopaminergic Neurons Against Mitochondrial Toxin MPP+. Presenter: Joanne Taylor, Ph.D., Senior Vice President of Research, Gain Therapeutics. Results from a Phase 1 study of GT-02287 in healthy volunteers demonstrated favorable safety and tolerability, plasma and CNS exposures in the projected therapeutic range, and target engagement with a >50% increase in glucocerebrosidase  activi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gain-therapeutics-announces-oral-poster-114500593.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4139","LU1169589451.USD","LU1169590202.USD","PD","BK4023","BK4588","GT","BK4119","GANX","BK4585","BK4007"],"gpt_icon":0},{"id":"2531037571","title":"CytoMed Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags","url":"https://stock-news.laohu8.com/highlight/detail?id=2531037571","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531037571?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:42","pubTimestamp":1746013364,"startTime":"0","endTime":"0","summary":"We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.NasdaqCM:GDTC Earnings and Revenue History April 30th 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 4.6%. Earnings per share  missed analyst estimates by 12%.The company's shares are up 2.0% from a week ago.We don't want to rain on the parade too much, but we did also find 4 warning signs for CytoMed Therapeutics (2 are significant!) that you need to be mindful of.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cytomed-therapeutics-full-2024-earnings-114244438.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GDTC","LENZ"],"gpt_icon":0},{"id":"2531036186","title":"Context Therapeutics presents preclinical data on CT-95","url":"https://stock-news.laohu8.com/highlight/detail?id=2531036186","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531036186?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:38","pubTimestamp":1746013116,"startTime":"0","endTime":"0","summary":"Context Therapeutics (CNTX) announced preclinical and translational data regarding the Company’s clinical asset, CT-95, a mesothelin x CD3 TCE was ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/context-therapeutics-presents-preclinical-data-on-ct-95?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/context-therapeutics-presents-preclinical-data-on-ct-95?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CNTX","LENZ","BK4139","BK4007"],"gpt_icon":0},{"id":"2531482035","title":"HC Wainwright Downgrades Springworks Therapeutics to Neutral From Buy, Adjusts Price Target to $47 From $74","url":"https://stock-news.laohu8.com/highlight/detail?id=2531482035","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531482035?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:34","pubTimestamp":1746012893,"startTime":"0","endTime":"0","summary":"Springworks Therapeutics (SWTX) has an average rating of Hold and mean price target of $51.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","SWTX"],"gpt_icon":0}],"pageSize":20,"totalPage":15,"pageCount":10,"totalSize":286,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LENZ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-07","symbol":"LENZ","fiscalQuarterEnding":"2025/03","expectedEps":-0.55,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"post","actualEps":-0.53},{"market":"US","date":"2024-05-08","symbol":"LENZ","fiscalQuarterEnding":"2024/03","expectedEps":-0.84,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715140800000,"reportTimeType":"pre","actualEps":-3.53},{"market":"US","date":"2024-03-22","symbol":"LENZ","defaultRemindTime":1711114200000,"type":"split","dateTimestamp":1711080000000,"forFactor":7,"toFactor":1,"ratio":7},{"date":"2024-03-22","symbol":"LENZ","amount":1.03,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-03-18","name":"Therapeutics","recordDate":"2024-03-21","payableDate":"2024-03-18","currency":"USD","dateTimestamp":1711080000000,"payDate":"2024-03-21"},{"market":"US","date":"2021-08-12","symbol":"LENZ","fiscalQuarterEnding":"2021/06","expectedEps":-1.11,"name":null,"time":"","type":"earning","dateTimestamp":1628740800000,"reportTimeType":"","actualEps":-3.45}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LENZ\",market:\"US\",,,undefined,":[{"executeDate":"2024-03-22","recordDate":"2024-03-18","paymentDate":"2024-03-21","value":1.03,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LENZ\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":8,"updateTime":1742270400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LENZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LENZ","date":"2025-05-08","current":-14.330679,"percent":0.167939,"low":-16.900596,"twenty":-14.111201,"median":-10.09248,"eighty":-6.449831,"high":-5.069183,"avg":-10.258063,"sd":3.310161,"marketCap":713223542},"quantilePoints":[{"date":"2024-03-28","current":-7.959158,"twenty":-7.219077,"median":-6.108955,"eighty":-6.016992,"marketCap":556886354},{"date":"2024-04-05","current":-7.492045,"twenty":-7.873034,"median":-7.667213,"eighty":-6.662191,"marketCap":524203432},{"date":"2024-04-12","current":-7.929963,"twenty":-7.855517,"median":-7.667213,"eighty":-7.432197,"marketCap":554843672},{"date":"2024-04-19","current":-6.382653,"twenty":-7.855517,"median":-7.488396,"eighty":-6.783348,"marketCap":446581492},{"date":"2024-04-26","current":-5.638193,"twenty":-7.716113,"median":-7.451903,"eighty":-5.889996,"marketCap":394493084},{"date":"2024-05-03","current":-5.988527,"twenty":-7.671592,"median":-6.864363,"eighty":-5.803142,"marketCap":419005276},{"date":"2024-05-10","current":-5.317808,"twenty":-7.667213,"median":-6.108955,"eighty":-5.803142,"marketCap":393230653},{"date":"2024-05-17","current":-5.708011,"twenty":-7.597146,"median":-6.0013,"eighty":-5.749862,"marketCap":422084590},{"date":"2024-05-24","current":-5.428308,"twenty":-7.489126,"median":-6.006774,"eighty":-5.719496,"marketCap":401401679},{"date":"2024-05-31","current":-5.355793,"twenty":-7.479638,"median":-5.988527,"eighty":-5.522773,"marketCap":396039443},{"date":"2024-06-07","current":-5.193496,"twenty":-7.457742,"median":-5.904593,"eighty":-5.428999,"marketCap":384038248},{"date":"2024-06-14","current":-6.433167,"twenty":-7.451903,"median":-5.930138,"eighty":-5.428308,"marketCap":475706952},{"date":"2024-06-21","current":-6.236339,"twenty":-7.425628,"median":-5.992177,"eighty":-5.43107,"marketCap":461152311},{"date":"2024-06-28","current":-6.150011,"twenty":-7.389135,"median":-6.0013,"eighty":-5.439358,"marketCap":454768696},{"date":"2024-07-05","current":-6.098214,"twenty":-7.269437,"median":-6.014073,"eighty":-5.469746,"marketCap":450938528},{"date":"2024-07-12","current":-6.771573,"twenty":-6.771573,"median":-6.098214,"eighty":-5.493918,"marketCap":500730721},{"date":"2024-07-15","current":-7.261916,"twenty":-7.163847,"median":-6.103393,"eighty":-5.509112,"marketCap":536989651},{"date":"2024-08-02","current":-8.498134,"twenty":-7.266429,"median":-6.108573,"eighty":-5.524305,"marketCap":628403011},{"date":"2024-08-09","current":-8.328931,"twenty":-7.474529,"median":-6.146558,"eighty":-5.597209,"marketCap":615891126},{"date":"2024-08-16","current":-8.944708,"twenty":-7.671592,"median":-6.236339,"eighty":-5.641258,"marketCap":621424629},{"date":"2024-08-23","current":-8.79431,"twenty":-7.94748,"median":-6.352018,"eighty":-5.670717,"marketCap":610975896},{"date":"2024-08-30","current":-8.746816,"twenty":-8.006409,"median":-6.382653,"eighty":-5.719496,"marketCap":607676296},{"date":"2024-09-06","current":-9.451311,"twenty":-8.199004,"median":-6.419354,"eighty":-5.743293,"marketCap":656620360},{"date":"2024-09-13","current":-8.17293,"twenty":-8.352945,"median":-6.434893,"eighty":-5.773217,"marketCap":567806132},{"date":"2024-09-20","current":-8.7389,"twenty":-8.507104,"median":-6.459289,"eighty":-5.788545,"marketCap":607126363},{"date":"2024-09-27","current":-8.806184,"twenty":-8.638371,"median":-6.616182,"eighty":-5.792924,"marketCap":611800796},{"date":"2024-10-04","current":-8.897214,"twenty":-8.745233,"median":-7.269437,"eighty":-5.800953,"marketCap":618125029},{"date":"2024-10-11","current":-9.340491,"twenty":-8.850511,"median":-7.455552,"eighty":-5.81701,"marketCap":648921294},{"date":"2024-10-18","current":-10.417023,"twenty":-8.905129,"median":-7.492045,"eighty":-5.857882,"marketCap":723712222},{"date":"2024-10-25","current":-9.902504,"twenty":-9.0017,"median":-7.670862,"eighty":-5.904593,"marketCap":687966558},{"date":"2024-10-31","current":-10.939457,"twenty":-9.257377,"median":-7.718702,"eighty":-5.904593,"marketCap":760007820},{"date":"2024-11-08","current":-14.709443,"twenty":-9.419648,"median":-7.959158,"eighty":-5.955683,"marketCap":894466512},{"date":"2024-11-15","current":-15.344855,"twenty":-9.514636,"median":-8.00261,"eighty":-5.970448,"marketCap":933105265},{"date":"2024-11-22","current":-15.521232,"twenty":-9.76398,"median":-8.132103,"eighty":-5.988527,"marketCap":943830613},{"date":"2024-11-29","current":-16.100113,"twenty":-9.924668,"median":-8.17293,"eighty":-5.994366,"marketCap":979031755},{"date":"2024-12-06","current":-16.33076,"twenty":-10.388526,"median":-8.285117,"eighty":-6.004584,"marketCap":993057210},{"date":"2024-12-13","current":-13.920266,"twenty":-10.815972,"median":-8.351032,"eighty":-6.018452,"marketCap":846477455},{"date":"2024-12-20","current":-13.694141,"twenty":-11.182468,"median":-8.50374,"eighty":-6.082845,"marketCap":832727009},{"date":"2024-12-27","current":-14.476534,"twenty":-12.093039,"median":-8.531114,"eighty":-6.098214,"marketCap":880303552},{"date":"2025-01-03","current":-12.794163,"twenty":-13.449021,"median":-8.618187,"eighty":-6.102358,"marketCap":778000234},{"date":"2025-01-10","current":-11.912274,"twenty":-13.190334,"median":-8.707238,"eighty":-6.108649,"marketCap":724373495},{"date":"2025-01-17","current":-10.130408,"twenty":-13.019383,"median":-8.746816,"eighty":-6.115785,"marketCap":616019980},{"date":"2025-01-24","current":-11.197719,"twenty":-12.871045,"median":-8.79431,"eighty":-6.143105,"marketCap":680922085},{"date":"2025-01-31","current":-11.523339,"twenty":-12.794163,"median":-8.877425,"eighty":-6.150011,"marketCap":700722728},{"date":"2025-02-07","current":-12.070562,"twenty":-12.328345,"median":-8.905129,"eighty":-6.232886,"marketCap":733998807},{"date":"2025-02-14","current":-11.432889,"twenty":-12.292165,"median":-8.964497,"eighty":-6.236339,"marketCap":695222549},{"date":"2025-02-21","current":-11.279124,"twenty":-12.151063,"median":-8.998138,"eighty":-6.308164,"marketCap":685872246},{"date":"2025-02-28","current":-9.62841,"twenty":-12.079607,"median":-9.059485,"eighty":-6.342695,"marketCap":585493990},{"date":"2025-03-07","current":-10.297741,"twenty":-11.943932,"median":-9.320702,"eighty":-6.355126,"marketCap":626195310},{"date":"2025-03-14","current":-11.193196,"twenty":-11.879712,"median":-9.419648,"eighty":-6.365485,"marketCap":680647077},{"date":"2025-03-21","current":-14.554795,"twenty":-11.943932,"median":-9.482973,"eighty":-6.379634,"marketCap":724377586},{"date":"2025-03-28","current":-14.68208,"twenty":-12.421509,"median":-9.574004,"eighty":-6.398202,"marketCap":730712447},{"date":"2025-04-04","current":-12.728528,"twenty":-13.089934,"median":-9.668992,"eighty":-6.415901,"marketCap":633486102},{"date":"2025-04-11","current":-10.2603,"twenty":-12.90813,"median":-9.741473,"eighty":-6.42488,"marketCap":510644883},{"date":"2025-04-17","current":-12.761733,"twenty":-12.945214,"median":-9.779811,"eighty":-6.430405,"marketCap":635138674},{"date":"2025-04-25","current":-15.833323,"twenty":-13.271407,"median":-9.84549,"eighty":-6.435239,"marketCap":788008663},{"date":"2025-05-02","current":-15.982746,"twenty":-13.932929,"median":-9.940463,"eighty":-6.440764,"marketCap":795445305},{"date":"2025-05-08","current":-14.330679,"twenty":-14.111201,"median":-10.09248,"eighty":-6.449831,"marketCap":713223542}],"updateTime":1746839443533}}}